We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $980M
1-Year Est. Return 470.8%
This Fund
S&P 500
This Quarter Est. Return
+7.72%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$247M
AUM Growth
+$69.9M
Cap. Flow
+$70.2M
Cap. Flow %
28.45%
Top 10 Hldgs %
43.11%
Holding
96
New
14
Increased
43
Reduced
12
Closed
25

Top Buys

Rank Stock Value
1
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$6.72M
2
APEN
Apollo Endosurgery, Inc.
APEN
+$6.46M
3
IMGN
Immunogen Inc
IMGN
+$5.37M
4
BLU
BELLUS Health Inc.
BLU
+$4.88M
5
BBIO icon
BridgeBio Pharma
BBIO
+$4.23M

Top Sells

Rank Stock Value
1
FULC icon
Fulcrum Therapeutics
FULC
+$5.24M
2
NXTC icon
NextCure
NXTC
+$3.68M
3
ARVN icon
Arvinas
ARVN
+$3.06M
4
INSM icon
Insmed
INSM
+$2.11M
5
ERAS icon
Erasca
ERAS
+$1.98M

Sector Composition

Rank Sector Weight
1 Healthcare 84.37%
2 Financials 5.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MSAC
51
DELISTED
Medicus Sciences Acquisition Corp. Class A Ordinary Share
MSAC
$1.25M 0.51%
128,582
+18,542
+17% +$180K
PYPD icon
52
PolyPid
PYPD
$78.2M
$1.24M 0.5%
7,187
+1,079
+18% +$228K
AKLI
53
DELISTED
Akili Inc
AKLI
$1.23M 0.5%
123,862
+17,862
+17% +$177K
PROK icon
54
ProKidney
PROK
$316M
$1.23M 0.5%
123,862
+17,862
+17% +$177K
DNAB
55
DELISTED
Social Capital Suvretta Holdings Corp. II Class A Ordinary Shares
DNAB
$1.23M 0.5%
123,862
+17,862
+17% +$177K
DNAD
56
DELISTED
Social Capital Suvretta Holdings Corp. IV Class A Ordinary Shares
DNAD
$1.22M 0.49%
123,862
+17,862
+17% +$176K
NXTC icon
57
NextCure
NXTC
$20.4M
$1.16M 0.47%
16,084
-44,025
-73% -$3.68M
PNT
58
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$1.15M 0.46%
204,462
+132,733
+185% +$996K
VRTX icon
59
Vertex Pharmaceuticals
VRTX
$123B
$1.1M 0.45%
+5,000
New +$972K
INBX
60
DELISTED
Inhibrx, Inc. Common Stock
INBX
$1.08M 0.44%
+24,666
New +$986K
CRIS icon
61
CALL
Curis
CRIS
$9.71M
$952K 0.39%
+500
New +$1.19M
KURA icon
62
Kura Oncology
KURA
$793M
$935K 0.38%
66,812
+10,198
+18% +$165K
IPHA
63
Innate Pharma
IPHA
$171M
$839K 0.34%
+184,046
New +$979K
VTGN icon
64
VistaGen Therapeutics
VTGN
$9.98M
$827K 0.34%
14,139
-9,452
-40% -$615K
CGEN icon
65
Compugen
CGEN
$212M
$699K 0.28%
162,602
-40,930
-20% -$221K
EVGN icon
66
Evogene
EVGN
$5.83M
$481K 0.19%
29,306
+4,473
+18% +$101K
MREO
67
Mereo BioPharma
MREO
$48.9M
$373K 0.15%
233,183
-132,478
-36% -$265K
CGEN icon
68
CALL
Compugen
CGEN
$212M
$245K 0.1%
57,000
-191,000
-77% -$1.03M
CALA
69
DELISTED
Calithera Biosciences, Inc
CALA
$146K 0.06%
10,990
+1,678
+18% +$42.2K
RCOR.WS
70
DELISTED
Renovacor, Inc. Warrants, entitling the holder thereof to purchase one-half (1/2) of a share of common stock at a price of $11. 50 per whole share
RCOR.WS
$60K 0.02%
104,828
– –
MSACW
71
DELISTED
Medicus Sciences Acquisition Corp. Warrant
MSACW
$36K 0.01%
49,990
– –
AFMD
72
DELISTED
Affimed
AFMD
– –
-4,718
Closed -$292K
ARCT icon
73
Arcturus Therapeutics
ARCT
$165M
– –
-6,208
Closed -$297K
ARVN icon
74
Arvinas
ARVN
$530M
– –
-37,249
Closed -$3.06M
LONA
75
LeonaBio Inc
LONA
$66.1M
– –
-10,639
Closed -$998K
1 2
3
4

Similar funds

BIP
Blueprint Investment Partners Greensboro, North Carolina $980M AUM 27.19% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $977M AUM 19.09% 1-Year Est. Return
FCM
Fortis Capital Management Bellevue, Washington $977M AUM 17.17% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
GFP
Gryphon Financial Partners Columbus, Ohio $976M AUM 23.05% 1-Year Est. Return
ADIC
Abu Dhabi Investment Council Abu Dhabi, United Arab Emirates $975M AUM
PCM
Politan Capital Management New York $985M AUM 3.12% 1-Year Est. Return

Silverarc Capital Management's Q4 2021 Portfolio in Review

As of Q4 2021, Silverarc Capital Management held 96 positions worth $247M, up 40% from $177M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Silverarc Capital Management deployed $70.2M of net new capital in Q4 2021, opening 14 new positions and adding to 43 existing holdings. Its largest new stake was Lakefront Biotherapeutics American Depositary Shares: 128,901 shares worth $7.11M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, down from 90% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was NextCure, an estimated $3.68M trimmed.

  • Silverarc Capital Management's largest Q4 2021 buy was Lakefront Biotherapeutics American Depositary Shares: 128,901 shares worth $7.11M.
  • Silverarc Capital Management added most to Immunogen Inc in Q4 2021, an estimated $5.37M increase.
  • Silverarc Capital Management's biggest Q4 2021 reduction was NextCure, cutting an estimated $3.68M.
  • Silverarc Capital Management fully exited Fulcrum Therapeutics in Q4 2021, selling an estimated $5.24M.
  • Silverarc Capital Management's ten largest holdings make up 43% of its $247M portfolio in Q4 2021.
  • Silverarc Capital Management opened 14 new positions and closed 25 in Q4 2021.
  • Silverarc Capital Management's portfolio value rose 40% quarter-over-quarter to $247M.

Based on Silverarc Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.